Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors
Public ClinicalTrials.gov record NCT04579757. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-Label Phase Ib/II Study of Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This open-label, phase Ib/II study of surufatinib in combination with tislelizumab will evaluate the safety, tolerability, PK and efficacy in patients with advanced solid tumors. The study consists of 2 parts - dose finding (Part 1) and dose expansion (Part 2).
Study identification
- NCT ID
- NCT04579757
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 87 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 5, 2021 (Actual)
- Primary completion
- Apr 30, 2024 (Actual)
- Completion
- Aug 27, 2024 (Actual)
- Last update posted
- May 8, 2025
2021 – 2024
United States locations
- U.S. sites
- 18
- U.S. states
- 13
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Arizona Oncology Associated, PC-HOPE | Tucson | Arizona | 85711 | — |
| City of Hope | Duarte | California | 91010 | — |
| Rocky Mountain Cancer Centers Midtown | Denver | Colorado | 80218 | — |
| Johns Hopkins University - Sibley Memorial Hospital | Washington D.C. | District of Columbia | 20016 | — |
| Emory University - Winship Cancer Institute | Atlanta | Georgia | 30322 | — |
| Holden Comprehensive Cancer Center, University of Iowa | Iowa City | Iowa | 52242 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10021 | — |
| University Hospitals Cleveland Medical Center | Cleveland | Ohio | 44106 | — |
| University of Pennsylvania, Perelman Center for Advanced Medicine | Philadelphia | Pennsylvania | 19104 | — |
| Prisma Health - Upstate (ITOR) | Greenville | South Carolina | 29605 | — |
| Sarah Cannon | Nashville | Tennessee | 37203 | — |
| Vanderbilt University Medical Center | Nashville | Tennessee | 37232 | — |
| Mary Crowley Cancer Research | Dallas | Texas | 75230 | — |
| Texas Oncology - Baylor Charles A. Sammons Cancer Center | Dallas | Texas | 75246 | — |
| Texas Oncology, P.A. | Fort Worth | Texas | 76104 | — |
| The University of Texas MD Anderson Cancer Center | Houston | Texas | 77079 | — |
| Texas Oncology, P.A. | Tyler | Texas | 75702 | — |
| Virginia Cancer Specialists, PC | Fairfax | Virginia | 22031 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04579757, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 8, 2025 · Synced Oct 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04579757 live on ClinicalTrials.gov.